PPN Facebook PPN Twitter PPN Instagram


Researchers aim to enroll 92 patients with a confirmed diagnosis of moderate to severe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) to determine the sustainability of the reduction of the severity of symptoms in children treated with intravenous human normal immunoglobulin and to assess its efficacy in reducing functional impairment associated with PANS. This is a randomised, double-blind, placebo-controlled superiority study.


  • 6-17 years in age
  • Onset of initial PANS symptoms was not more than 6 months prior to planned Screening. Or, for children with relapsing symptoms, the initial symptoms were less than 12 months prior to Screening and recurrence is within 6 months of Screening
  • Moderate to severe PANS with prominent and stable obsessive-compulsive disorder symptoms
  • Do not have symptoms consistent with autism, schizophrenia, bipolar disorder, or any other psychiatric disorder

For the full list of criteria and exclusions, please visit the clinical trial page. (Identifier: NCT04508530)

For more information about enrollment, please contact:

Snehal Udavat
Clinical operations at Octapharma USA, Inc.